Interestingly, treatment with LiCl significantly attenuated tau phosphorylation in the LV of T2DM rats when administered either daily or every other day by increasing GSK-3β phosphorylation at its inhibitory site Ser9 (Figure 1A–D). Here, MAPT is linked to type 2 diabetes mellitus.